...Newco Thunderbolt acquired Astellas’ preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF...
...to treat B cell-mediated disorders, including systemic lupus erythematosus (SLE). The terms are not disclosed. Thunderbolt...
...development costs of the BAFF/TNF program. Velocity said Astellas received an undisclosed equity stake in Thunderbolt...

...Vitesse Biologics LLC (South San Francisco, Calif.) launched virtual newco Thunderbolt Pharma Inc. (South San Francisco, Calif.), which...
...13 ( TNFSF13 ; APRIL) to treat B cell-mediated disorders including systemic lupus erythematosus (SLE). Thunderbolt...
...SVP of Business Development Stuart Sedlack said Astellas received an undisclosed equity stake in Thunderbolt. Thunderbolt...